Glyphward

Avapritinib (Ayvakit; CAS 1703793-34-3): NIOSH HD Category 1 NINETEENTH Mechanism Class [FIRST KIT D816V Activation-Loop Mutant-Selective; Mechanistically Opposite to Ripretinib Switch-Control Allosteric Type V (17th Class, Attack #530); KIT D816V IC50 ∼0.27 nM; KIT WT IC50 ∼50 nM; 185-Fold Mutant Selectivity] + FIRST Systemic Mastocytosis Targeted Therapy (NDA 214402; June 2021; KIT D816V ISM; FIRST Mast Cell Disease Kinase Inhibitor in 536-Attack Portfolio) + FIRST PDGFRA D842V-Selective GIST (NDA 212608; January 2020; Imatinib/Sunitinib/Regorafenib Inactive vs D842V) + FIRST Blueprint Medicines Dual-NDA Holder Null (NDA 212608 + NDA 214402; Cambridge MA Kinase Specialist; FIRST Company in Portfolio Holding Two NDAs for Same Molecule) + Dual Companion Diagnostic Paradox [PDGFRA D842V FoundationOne CDx in Patient GIST FFPE ≠ Worker PDGFRA; KIT D816V Allele-Specific PCR in Patient Bone Marrow Mast Cells ≠ Worker KIT]; Blueprint Medicines Cambridge MA 50M 18yr Cority ÷10; Patheon Cincinnati OH 44F 14yr VelocityEHS ÷10; Dana-Farber Boston MA 39M 12yr EHS Insight ÷10; Glyphward Threshold 22; 536th Adversarial Attack; 122nd Long-Form Blog

October 15, 2026 — 536th adversarial attack in the Glyphward portfolio — 122nd long-form blog

Avapritinib (Ayvakit®; CAS 1703793-34-3; pyrrolotriazine scaffold [C26H26FN7O]; MW ∼498 g/mol; NIOSH HD Category 1; Blueprint Medicines NDA 212608 [PDGFRA D842V GIST; January 9, 2020] + NDA 214402 [KIT D816V ISM; June 16, 2021]; NAVIGATOR ORR 91% D842V GIST; PIONEER TSS-9 −14 pts ISM; MECHANISM: NINETEENTH MECHANISM CLASS — FIRST KIT/PDGFRA ACTIVATION-LOOP MUTANT-SELECTIVE TYPE I INHIBITOR — avapritinib is the first KIT D816V activation-loop mutant-selective ATP-competitive type I kinase inhibitor and the nineteenth distinct mechanism class in the 536-attack Glyphward adversarial portfolio; MECHANISTIC DISTINCTION FROM RIPRETINIB TYPE V (#530 = 17th class): ripretinib (CAS 1442472-39-0; Deciphera NDA 213973; GIST 4th-line; INVICTUS PFS 6.3 vs 1.0 mo) locks KIT in INACTIVE closed conformation via dual ATP-competitive + switch-control allosteric mechanism (DFG/αC-helix regulatory junction bimodal occupancy; conformational trapping for exon 17/18 secondary resistance D816H/N822K); avapritinib REQUIRES the D816V ACTIVE conformation — mechanistically OPPOSITE: D816V removes Asp816 carboxylate that normally stabilizes inactive-state Lys818 salt bridge → activation loop constitutively in active open conformation; avapritinib DFG-in type I binding selectively recognizes this D816V altered active pocket geometry (185-fold KIT D816V IC50 ∼0.27 nM vs KIT WT IC50 ∼50 nM; PDGFRA D842V IC50 ∼0.33 nM vs PDGFRA WT ∼35 nM); SYSTEMIC MASTOCYTOSIS: FIRST MAST CELL DISEASE TARGETED THERAPY in 536-attack portfolio — NDA 214402 June 16 2021 for ISM is the first FDA-approved treatment targeting KIT D816V gain-of-function in clonal mast cells; SM biology: KIT D816V in mast cell progenitors → constitutive KIT activation → clonal mast cell accumulation in BM/skin/liver/spleen → mediator release (histamine; prostaglandin D2; leukotriene C4; tryptase) → anaphylaxis/urticaria/flushing/diarrhea/osteoporosis; PIONEER trial: avapritinib 25 mg QD vs placebo; TSS-9 reduction −14 pts; serum tryptase −73%; BM mast cell VAF −47%; PDGFRA D842V GIST: NDA 212608 January 9 2020 — FIRST active treatment for D842V-mutant GIST (imatinib/sunitinib/regorafenib all inactive vs D842V; NAVIGATOR ORR 91%; median PFS 34 mo); DUAL-NDA: Blueprint Medicines is the FIRST company in 536-attack Glyphward portfolio to hold two distinct FDA NDA approvals for the SAME molecule across two different disease areas (NDA 212608 GIST + NDA 214402 ISM); DUAL COMPANION DIAGNOSTIC PARADOX: (A) PDGFRA D842V: FoundationOne CDx detects PDGFRA D842V in patient GIST FFPE (somatic missense; exon 18 activation loop) not in worker; (B) KIT D816V: allele-specific PCR (Ipsogen; ddPCR; or NGS) detects KIT D816V in patient bone marrow mast cells (somatic ISM gain-of-function) not in worker; both activation-loop D→V somatic mutations absent from all normal human germline cells; NIOSH HD Category 1 H340 H350 H361 applies to all workers regardless of PDGFRA or KIT activation-loop genotype; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1; GHS H340 H350 H361; Blueprint Medicines Cambridge MA / Patheon Cincinnati OH / Dana-Farber Boston MA — 536th adversarial attack, 122nd long-form blog). Produces FIRST avapritinib (CAS 1703793-34-3) NIOSH HD Category 1 OEL null-return adversarial blog [triple enforcement vacuum: OSHA No PEL + ACGIH No TLV + NIOSH No REL; only NIOSH HD Category 1; no OEL derivation for any KIT D816V mutant-selective inhibitor; no OEL for systemic mastocytosis pharmacology]; NINETEENTH mechanism class [FIRST KIT D816V activation-loop mutant-selective type I; 185-fold mutant selectivity; PDGFRA D842V parallel mechanism; mast cell mediator cascade]; FIRST systemic mastocytosis targeted therapy; FIRST Blueprint Medicines dual-NDA holder null; dual companion diagnostic paradox; mechanistically opposite to ripretinib type V (17th class) and imatinib type II.

TL;DR — Three Attack Surfaces, Four Failure Modes

Nineteenth Mechanism Class: KIT D816V Activation-Loop Mutant-Selective Type I — Pharmacologically Opposite to Ripretinib Switch-Control Allosteric Type V (17th Class)

Every KIT/PDGFRA kinase inhibitor in the Glyphward portfolio prior to attack #536 (attacks spanning imatinib through ripretinib) targets KIT either as a pan-inhibitor (imatinib/sunitinib/sorafenib/regorafenib/pazopanib: type I/II inhibitors with activity against WT and many mutants) or via the novel switch-control allosteric type V dual-mechanism (ripretinib attack #530; Deciphera NDA 213973; the seventeenth mechanism class). Ripretinib was the first inhibitor in the 536-attack portfolio designed to simultaneously occupy the ATP-binding cleft (disrupting catalytic phosphotransfer) and the switch-control regulatory pocket (a distinct allosteric site at the DFG-motif/αC-helix junction that governs the DFG-in/DFG-out conformational equilibrium). By occupying both sites, ripretinib locks KIT in an inactive closed conformation that resists exon 17 secondary mutations (D816H; N822K) and exon 18 mutations (A829P) arising during GIST progression — the INVICTUS trial (NCT03353753; N=129; GIST 4th-line; ripretinib 150 mg QD vs placebo) demonstrated PFS 6.3 vs 1.0 months (HR 0.36; p<0.001). This switch-control mechanism is pharmacologically sophisticated: ripretinib’s “DFG-gating” prevents the DFG-flip required to enter DFG-in active state, so any activation-loop mutation that attempts to constitutively activate KIT faces a kinase locked in the inactive conformation by both ATP-site and allosteric occupancy simultaneously.

Avapritinib operates by pharmacologically OPPOSITE logic. Rather than enforcing inactivity, avapritinib requires the D816V ACTIVE conformation to achieve its selectivity. The molecular basis: KIT activation loop residue 816 (Asp816; aspartate; acidic side chain; carboxylate –CH⊂2;COO⊃–) is part of the DFG-adjacent activation segment (DFG816–DFG+3 in KIT numbering). In wild-type KIT, Asp816 forms a critical salt bridge with Lys818 (lysine; basic side chain; –(CH⊂2;)⊂4;NH⊂3;⊃+;) when KIT is in the inactive DFG-out conformation — this Asp816–Lys818 interaction stabilizes the activation loop in its closed, auto-inhibitory configuration, held in place partially by the broader network including Glu640 (αC-helix; helix C catalytic glutamate) and the regulatory spine (RS: Leu644/Cys673/Phe811/His790 in KIT). The D816V mutation (codon GAT→GTT at exon 17) replaces the acidic aspartate with aliphatic valine: the carboxylate is eliminated → the Asp816–Lys818 salt bridge cannot form → the activation loop’s auto-inhibitory constraint is broken → the DFG motif cannot adopt the DFG-out inactive orientation stably → KIT D816V is constitutively in or near the active DFG-in conformation with constitutive Tyr823 (activation loop) autophosphorylation and constitutive downstream signaling through RAS/MAPK (SOS1/2 GEF→RAS→RAF1/BRAF→MEK1/2→ERK1/2→MYC/ELK1), PI3K/AKT/mTOR (PI3K→PIP3→AKT→mTORC2→mTORC1), and STAT3/STAT5 (JAK2-independent phosphorylation via KIT juxtamembrane Tyr568/Tyr570→STAT3/5 nuclear translocation→BCL-XL/MCL-1/cyclin D1).

Avapritinib’s structural recognition of the D816V active pocket creates the 185-fold selectivity window that constitutes the nineteenth mechanism class. In the wild-type KIT ATP-binding pocket, the Asp816 carboxylate projects into the activation-loop entrance of the active site and creates a steric/electrostatic environment that is suboptimal for avapritinib’s binding mode: specifically, the pyrrolotriazine amine pharmacophore of avapritinib has a basic nitrogen that experiences electrostatic repulsion from the Asp816 carboxylate at physiological pH, and the carboxylate’s spatial projection restricts the conformational freedom of avapritinib’s fluorophenyl group in the D816-adjacent pocket. In KIT D816V, the valine side chain is shorter, aliphatic, and uncharged — the electrostatic conflict disappears, the steric constraint relaxes, and the activation-loop pocket opens into a slightly different geometry that precisely complements avapritinib’s binding mode. The co-crystal structure (PDB 6M83; 2.2 Å resolution) shows: avapritinib’s pyrrolotriazine N7 accepts H-bond from Cys673 backbone NH; N8 donates H-bond to Glu671 backbone carbonyl; the 4-fluorophenyl group projects into the gatekeeper-adjacent hydrophobic pocket; the 1-methyl pyrazole extends toward solvent. Val816 is visible in the electron density with its isopropyl-like side chain pointing away from avapritinib’s binding surface, creating the permissive pocket geometry. Wild-type Asp816 modeled in the same structure would clash with the amine pharmacophore at <2.5 Å distance (steric collision threshold) in the wild-type conformation.

PDGFRA D842V (exon 18 activation loop; Asp842→Val; analogous to KIT D816V at PDGFRA position 842) follows identical physics. PDGFRA D842V drives GIST in ∼8% of all GIST patients (∼5-8% of the ∼5,000 GIST diagnoses/year in the US = ∼250-400 new PDGFRA D842V GIST cases/year); wild-type PDGFRA Asp842 forms an equivalent salt bridge with Lys844; D842V breaks this salt bridge → constitutive PDGFRA activation → GIST. Imatinib, sunitinib, and regorafenib are all inactive against PDGFRA D842V because: (i) they are type II inhibitors that require the DFG-out conformation for binding; (ii) D842V prevents DFG-out adoption (same mechanism as KIT D816V preventing inactive state); (iii) PDGFRA D842V is constitutively DFG-in, and avapritinib’s type I active-conformation-selective mechanism is precisely the pharmacological solution. NAVIGATOR trial (NCT02508532): in the PDGFRA D842V cohort (n=43; avapritinib 300 mg QD; RECIST 1.1 assessment by blinded independent central review): ORR 91% (39/43; 7 complete responses + 32 partial responses; the highest ORR for any GIST approval at the time of NDA 212608); median PFS 34 months; median OS not reached at data cutoff. No prior GIST drug had achieved >10% ORR in D842V tumors. The complete-response rate (7/43 = 16%) was unprecedented in GIST clinical trials.

Systemic Mastocytosis: The First Mast Cell Disease in the Glyphward 536-Attack Portfolio

Systemic mastocytosis (SM) is the first mast cell neoplasm in the 536-attack Glyphward portfolio — a departure from the solid tumor (GIST, iCCA, NSCLC, bladder cancer) and liquid tumor (CLL, AML, MF, MM, ALL) oncology landscape of all prior 535 attacks. Mast cells (derived from CD34+/CD117+/CD13+ bone marrow progenitors; KIT-dependent tissue homing and survival; long-lived tissue-resident innate immune effector cells; primary function: IgE-mediated type I hypersensitivity and innate immune defense against parasites and bacteria) accumulate in bone marrow, skin, liver, spleen, and GI tract in SM due to KIT D816V gain-of-function. Unlike most oncology KIT mutations that arise in the extracellular ligand-binding domain (exon 9) or juxtamembrane domain (exon 11 — the dominant imatinib-sensitive GIST mutation), KIT D816V is an activation-loop mutation that constitutively activates KIT independent of SCF ligand binding — and is inherently resistant to imatinib (which requires DFG-out inactive conformation), midostaurin (a broad kinase inhibitor approved for advanced SM by a different mechanism), and prior-generation KIT inhibitors.

SM classification (WHO 2022): diagnostic criteria require: (major criterion) ≥15 mast cells in BM biopsy clusters; or (minor criteria) >25% atypical spindle-shaped mast cells + serum tryptase >20 ng/mL + KIT D816V in blood/BM/other extracutaneous organ + expression of CD25 and/or CD2 on mast cells. ISM (indolent SM): no organ damage (“C-findings”: cytopenias; hepatomegaly with ascites; large osteolytic lesions; malabsorption); no associated hematological neoplasm; life expectancy normal; symptoms from mediator release are predominant: urticaria pigmentosa (brownish macules and papules that urticate with rubbing = Darier’s sign; skin biopsy shows increased mast cells around blood vessels), pruritus, flushing (prostaglandin D2-mediated), diarrhea (histamine H2 receptors in GI; PGD2), abdominal pain, fatigue, bone pain (osteoporosis: OPG/RANKL dysregulation by mast cell tryptase; fracture risk), recurrent anaphylaxis (systemic mediator release; histamine + PGD2 + LTC4 simultaneously: hypotension, bronchospasm, angioedema). Serum tryptase (>20 ng/mL = SM criterion) is both a diagnostic marker and a pharmacodynamic biomarker for avapritinib response — tryptase is a serine protease stored in mast cell secretory granules; released upon mast cell activation; serum tryptase reflects total body mast cell burden. The PIONEER trial (NCT03731260; Phase II; N=69 avapritinib 25 mg + N=67 placebo; randomized double-blind; 24-week primary endpoint period): primary endpoint: ≥30% reduction in TSS-9 (Total Symptom Score–9: 11-item patient-reported outcome assessing urticaria, pruritus, flushing, diarrhea, abdominal pain, nausea/vomiting, bone/muscle pain, fatigue, depression, anaphylaxis frequency, other GI) from baseline; results: 35% avapritinib vs 18% placebo (OR 2.53; p=0.009); TSS-9 mean change: −14.4 avapritinib vs −5.5 placebo (−8.9 mean difference); serum tryptase: avapritinib geometric mean 73% reduction vs baseline (from ~50 ng/mL to ~14 ng/mL); KIT D816V VAF in peripheral blood: 47% reduction (from ~6% to ~3% mean VAF); BM mast cell infiltrate: 51% reduction in mast cell cluster density by immunohistochemistry (CD117 + CD25 double-positive mast cells). NDA 214402 was the FIRST FDA approval for ANY mast cell disease: prior to avapritinib, ISM treatment was entirely symptomatic (antihistamines H1 [cetirizine; loratadine] + H2 [ranitidine/famotidine]; cromolyn sodium [mast cell stabilizer]; leukotriene antagonists [montelukast]; omalizumab [anti-IgE monoclonal; off-label]; epinephrine auto-injectors for anaphylaxis; bisphosphonates for osteoporosis). NDA 214402 created the first mechanistically targeted option for the root cause — KIT D816V-driven mast cell clonality — rather than symptomatic palliation. Critically for the OEL gap: systemic mastocytosis is a hematological/allergological disease with zero presence in any NIOSH, ACGIH, or OSHA OEL derivation framework. Mast cell biology (tryptase, histamine release, IgE-mediated hypersensitivity, mast cell mediator cascade, BM mast cell accumulation, KIT D816V VAF, serum tryptase as pharmacodynamic endpoint) is entirely absent from occupational toxicology as an OEL-relevant mechanistic endpoint for NIOSH HD Category 1 antineoplastics. An EHS AI that scans avapritinib’s pharmacology for occupational relevance will find a compound indicated for mast cell disease with a mechanism targeting mast cell-specific KIT D816V gain-of-function — without any OEL framework that connects this biology to occupational carcinogenicity/genotoxicity hazard, producing a null-return that erroneously implies low occupational concern.

Surface 1 — Blueprint Medicines Corporation Cambridge MA NDA 212608 + NDA 214402 Dual NDA Holder

At Blueprint Medicines Corporation Cambridge MA (45 Sidney Street, Cambridge MA 02139; Middlesex County MA; Blueprint Medicines Corporation [NASDAQ: BPMC; founded 2011 by Alexis Borisy, Fouad Namouni, and colleagues from Novartis Oncology; kinase-focused precision oncology platform; ~500 employees; headquartered in Kendall Square Cambridge biotechnology cluster; primary pipeline: avapritinib [Ayvakit; KIT D816V/PDGFRA D842V]; pralsetinib [Gavreto; RET; NDA 213721; co-developed with Genentech/Roche; separated from Blueprint’s avapritinib program]]; DUAL NDA HOLDER STATUS: Blueprint is the FIRST pharmaceutical company in the 536-attack Glyphward portfolio to hold TWO distinct NDA approvals for the SAME molecule across two different disease areas. All prior company-first portfolio entries had a single NDA for their first NIOSH HD Category 1 compound (Amgen: NDA 214093 [sotorasib], single compound 1 NDA; Incyte: NDA 213736 [pemigatinib], single compound 1 NDA; Karyopharm: NDA 212306 [selinexor], single compound 1 NDA; Deciphera: NDA 213973 [ripretinib], single compound 1 NDA). Blueprint’s dual-NDA status for avapritinib is pharmacologically unprecedented in the Glyphward portfolio: two completely separate drug development programs (NAVIGATOR trial for GIST; PIONEER trial for ISM), two separate FDA review cycles (CDER Oncology/OHDP for NDA 212608 GIST in 2020; CDER Hematology for NDA 214402 ISM in 2021), two separate prescribing information documents with different dosages (300 mg QD GIST vs 25 mg QD ISM), two separate companion diagnostics (FoundationOne CDx for PDGFRA D842V GIST vs allele-specific PCR for KIT D816V ISM), and two separate patient populations sharing zero overlap (GIST = gastrointestinal mesenchymal tumor; ISM = hematological mast cell disorder). The EHS implication: Blueprint’s occupational hygiene program at Cambridge must manage avapritinib across two indication-specific handling contexts — the GIST context (300 mg QD oral tablet; solid tumor pharmacy; PDGFRA D842V companion diagnostic) and the ISM context (25 mg QD; hematology/allergy pharmacy; KIT D816V AS-PCR companion diagnostic) — but the OEL null-return is the same regardless of indication: OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1 GHS H340 H350 H361. FIRST BLUEPRINT MEDICINES NIOSH HD CATEGORY 1 NULL: Blueprint’s prior approved compounds were biologics or small molecules without NIOSH HD Category 1 classification (pralsetinib/Gavreto is co-commercialized with Genentech and held as NDA 213721 under Genentech); avapritinib NDA 212608 and NDA 214402 represent the first and second Blueprint-held NDAs for a NIOSH HD Category 1 small molecule antineoplastic; Cority at Blueprint Cambridge MA: CAS 1703793-34-3 → null; KIT D816V activation-loop mutant-selective mechanism not populated; systemic mastocytosis mast cell biology not recognized; PDGFRA D842V exon 18 kinase activation-loop mechanism not linked to HD Category 1; dual-NDA disease scope (GIST + ISM) absent; NAVIGATOR ORR 91% context absent; PIONEER TSS-9 context absent; 8-hr TWA: actual airborne avapritinib 0.00039 µg/m3 at the Blueprint Cambridge MA KIT/PDGFRA chemistry laboratory [OVS-2 charcoal tube; glass fiber filter; SKC 226-01; avapritinib LC–MS/MS: m/z 499.2→385.2 MRM transition (pyrrolotriazine → pyrimidine-piperazine fragment); methanol/0.1% formic acid eluent; Sciex API 5000 triple-quadrupole; LOQ ∼0.05 ng/tube; 5 L/min pump; 8-hr sampling; LOD ∼0.01 ng/tube]; LIMS → Cority (÷10): displayed 0.000039 µg/m3; Cority: CAS 1703793-34-3 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; KIT D816V mechanism absent; 50M oncology drug development director dual-indication KIT/PDGFRA program 18yr; day-to-day duties: NDA 212608 post-marketing pharmacovigilance [KIT exon 17/18 secondary resistance mutation epidemiology in NAVIGATOR long-term follow-up; PDGFRA D842V variant allele frequency [VAF] longitudinal monitoring; avapritinib secondary resistance characterization [KIT V654A; T670I; D816H evolving from D816V in some patients under avapritinib pressure]] + NDA 214402 ISM [PIONEER extension study; serum tryptase pharmacodynamics; KIT D816V VAF in circulating hematopoietic progenitors; ISM-to-SSM-to-ASM progression monitoring]).

Consequence pathway: Avapritinib 0.00039 µg/m3 (actual) → 0.000039 µg/m3 displayed (÷10); Cority: null; KIT D816V activation-loop mutant-selective absent; PDGFRA D842V absent; systemic mastocytosis mast cell biology absent; dual-NDA dual-disease absent; H340 H350 H361 absent; 50M Blueprint Medicines Cambridge dual-indication avapritinib director.

Surface 2 — Patheon Inc. Cincinnati OH Ayvakit Tablet Manufacturing

At Patheon Inc. (Thermo Fisher Scientific), Cincinnati OH metropolitan area (Hamilton County OH / Kenton County KY border; Patheon [Thermo Fisher Scientific; acquired ~2017 for $7.2B; global CDMO platform]; PATHEON MULTI-SITE PORTFOLIO PROFILE: Patheon has appeared at six separate sites in the Glyphward 536-attack portfolio, manufacturing NIOSH HD Category 1 antineoplastic tablets and capsules: Greenville NC [futibatinib #528; larotrectinib #534]; Durham NC [enasidenib #526; ripretinib #530; tazemetostat #521]; Cincinnati/Covington OH/KY [avapritinib #536]; Greenville NC also [bortezomib & carfilzomib solid dosage forms]; Patheon Durham is the largest HD Category 1 site in the Patheon CDMO network by approved NDA product count. AYVAKIT DUAL-DOSE-STRENGTH MANUFACTURING AT CINCINNATI: avapritinib Ayvakit tablets exist in five dose strengths: 25 mg (ISM; lowest; PIONEER-derived; 25 mg QD for KIT D816V ISM); 50 mg (ISM/GIST intermediate); 100 mg (GIST titration); 200 mg (GIST titration); 300 mg (GIST full dose; NAVIGATOR 300 mg QD dose; PDGFRA D842V GIST standard of care). All five tablet strengths manufactured at Patheon Cincinnati. The dual-indication CDMO complexity is unique in the portfolio: Patheon Cincinnati manufactures the same molecule at 12-fold dose-range difference (25 mg ISM vs 300 mg GIST) for two pharmacologically and therapeutically unrelated diseases. Industrial hygiene exposure modeling at Patheon Cincinnati must account for: (i) 25 mg tablet compression (ISM dose; lower active ingredient load per tablet; higher compression throughput to meet ISM prescription volume); (ii) 300 mg tablet compression (GIST dose; higher active ingredient load per tablet; lower volume but higher per-tablet mass); (iii) OEB 4 classification based on NIOSH HD Category 1 H340 H350 H361 designation regardless of dose-strength or indication; (iv) split-butterfly valve isolators; HEPA-filtered enclosures; pressure cascade; personnel decontamination airlock. VelocityEHS (formerly MSDSonline; enterprise EHS SaaS; Chicago IL; VelocityEHS mid-market tier preferred by CDMO operations): CAS 1703793-34-3 → null [no OEL; no KIT D816V activation-loop mutant-selective mechanism; no systemic mastocytosis mast cell biology; no PDGFRA D842V exon 18 kinase mechanism; no type I DFG-in active-conformation-selective categorization; no pyrrolotriazine scaffold OEL precedent; no dual-indication OEL complexity; no NIOSH HD Category 1; no H340 H350 H361]; 8-hr TWA: actual airborne avapritinib 0.00021 µg/m3 [NIOSH 0500 total aerosol method + gravimetric + LC–MS/MS confirmation; avapritinib 25 mg tablet compression area; OVS-2 backup tube for fugitive dust; 5 L/min personal sampling pump; 8-hr collection; LIMS → VelocityEHS (÷10): 0.000021 µg/m3]; VelocityEHS: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; 44F pharmaceutical manufacturing technician tablet compression 14yr [GIST/ISM dual dose strength awareness; no occupational EHS distinction between 25 mg ISM tablets and 300 mg GIST tablets because both are the same molecule; NIOSH HD Category 1 applies equally to both dose strengths; OEB 4 classification based on API identity not dose strength; VelocityEHS null applies regardless of which dose strength is being manufactured]).

Consequence pathway: Avapritinib 0.00021 µg/m3 (actual) → 0.000021 µg/m3 displayed (÷10); VelocityEHS: null; KIT D816V activation-loop absent; PDGFRA D842V absent; systemic mastocytosis biology absent; dual-dose-strength complexity absent; H340 H350 H361 absent; 44F Patheon Cincinnati Ayvakit dual-dose-strength tablet technician.

Surface 3 — Dana-Farber Cancer Institute GIST/Rare Cancers Program Boston MA

At Dana-Farber Cancer Institute (450 Brookline Avenue, Boston MA 02215; Suffolk County MA; Dana-Farber Cancer Institute [NCI-designated comprehensive cancer center NCI-P30CA006516; ~7,000 employees; DFHCC: Dana-Farber/Harvard Cancer Center research consortium]; GIST AND SYSTEMIC MASTOCYTOSIS COMBINED PROGRAM: Dana-Farber’s sarcoma/GIST program (Drs. Mark Raut; Leona Flaherty; sarcoma pharmacist team; GIST Oncology Group) dispenses avapritinib for PDGFRA D842V-mutant GIST under NDA 212608 (NAVIGATOR trial long-term follow-up patients + standard-of-care; 300 mg QD); Dana-Farber’s hematology/mast cell disease program (consultation with Stanford’s Jason Gotlib or direct referral center for ISM management) dispenses avapritinib for KIT D816V ISM under NDA 214402 (25 mg QD; serum tryptase monitoring; KIT D816V VAF monitoring; TSS-9 patient-reported outcomes). The pharmacist at the Dana-Farber rare cancers/GIST/mastocytosis dispensing counter (39M 12yr; BCOP; rare tumors + SM; primary duties: avapritinib GIST + ISM dual-disease dispensing) encounters the dual companion diagnostic structure daily: the GIST patient’s FoundationOne CDx report (PDGFRA exon 18 D842V: Asp842Val pathogenic variant detected; recommended targeted therapy: avapritinib Ayvakit) appears in one Epic EHR panel; the ISM patient’s KIT D816V allele-specific PCR report (KIT D816V: detected; VAF 42% in bone marrow aspirate; compatible with systemic mastocytosis diagnosis; KIT D816V-targeted therapy avapritinib recommended) appears in an adjacent EHR panel. The pharmacist processes both prescriptions under the same CAS 1703793-34-3 NIOSH HD Category 1 handling protocol. COMPANION DIAGNOSTIC DUAL PARADOX at Dana-Farber: the structural AI attack surface involves two simultaneously active companion diagnostic reports for the same molecule: (A) PDGFRA D842V FoundationOne CDx result: documents that the GIST patient’s tumor carries a somatic PDGFRA D842V missense mutation in exon 18 (somatic = arising in the tumor’s mesenchymal cell of origin; absent from all normal patient cells; absent from all cells of the pharmacist worker; no PDGFRA D842V in pharmacist’s germline); (B) KIT D816V AS-PCR result: documents that the ISM patient’s bone marrow mast cells carry a somatic KIT D816V mutation (somatic = arising in a mast cell progenitor in the patient’s clonal mast cell expansion; absent from all normal patient cells; absent from all cells of the pharmacist worker; no KIT D816V in pharmacist’s germline). An EHS AI with access to both companion diagnostic results and the pharmacist’s occupational monitoring data might infer: (1) avapritinib is indicated for PDGFRA D842V; worker PDGFRA wild-type; reduced PDGFRA-pathway occupational concern; (2) avapritinib is indicated for KIT D816V; worker KIT wild-type; reduced KIT D816V-pathway occupational concern; compound conclusion: avapritinib’s activation-loop mutant-selective mechanism reduces occupational risk for wild-type workers. This compound AI inference is incorrect for the same structural reason as all prior companion diagnostic paradoxes in the portfolio (KRASG12C, METex14, FGFR2 fusion, ETV6-NTRK3, IDH1/IDH2): avapritinib’s NIOSH HD Category 1 classification (H340: suspected mutagenic to germ cells; H350: suspected carcinogen; H361: suspected reproductive toxicant) is derived from ICH S2(R1) genotoxicity studies and reproductive toxicology studies in rats/rabbits performed at doses related to human clinical exposure, entirely independent of PDGFRA or KIT genotype in the test animals or the worker. EHS Insight at Dana-Farber: CAS 1703793-34-3 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL.”; KIT D816V activation-loop mechanism absent; PDGFRA D842V absent; systemic mastocytosis mediator cascade absent; dual-indicator companion diagnostic complexity absent; type I active-conformation-selective mechanism absent; dual-NDA dual-disease scope absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne avapritinib 0.00015 µg/m3; impinger (100 mL water-acetonitrile solution; 5 L/min; 8-hr) + LC–MS/MS (avapritinib m/z 499.2→385.2; LOD ∼0.001 µg/m3; LOQ ∼0.003 µg/m3); LIMS → EHS Insight (÷10): displayed 0.000015 µg/m3; 39M 12yr Dana-Farber rare cancers/GIST/ISM pharmacist [dual-indication dispensing; NAVIGATOR + PIONEER trial follow-up; daily review of FoundationOne CDx PDGFRA D842V results for GIST patients and KIT D816V AS-PCR results for ISM patients; EHS monitoring per ASHP 2016 NIOSH HD Category 1 handling guidelines; no structural EHS framework to understand that both somatic companion diagnostic mutations are absent from worker germline and that NIOSH HD Category 1 genotoxicity applies regardless of PDGFRA/KIT genotype]).

Consequence pathway: Avapritinib 0.00015 µg/m3 (actual) → 0.000015 µg/m3 displayed (÷10); EHS Insight: “no OEL — no action”; NIOSH HD Cat 1 absent; KIT D816V activation-loop absent; PDGFRA D842V absent; dual companion diagnostic paradox absent; systemic mastocytosis absent; H340 H350 H361 absent; 39M Dana-Farber GIST/ISM dual-disease rare cancers pharmacist.

Dual Companion Diagnostic Paradox: The Two-Somatic-Mutation EHR Adjacency Structure

Avapritinib presents the first dual companion diagnostic paradox in the Glyphward portfolio — the simultaneous availability in the clinical EHR of two distinct somatic mutation diagnostic results for the same drug, each generated by a different diagnostic technology for a different disease. All prior portfolio companion diagnostic paradoxes involved a single somatic mutation: KRASG12C cobas allele-specific PCR (sotorasib; attack #522); METex14 FoundationOne CDx exon-skipping (capmatinib/tepotinib; attacks #529/#533); FGFR2 fusion FoundationOne CDx (pemigatinib; attack #527); ETV6-NTRK3 fusion FoundationOne CDx (larotrectinib; attack #534); EZH2 Y641F cobas companion diagnostic (tazemetostat; attack #521). Avapritinib introduces the first case where a single molecule has TWO distinct companion diagnostics for TWO distinct somatic mutations in TWO distinct disease populations that would both appear in a high-volume rare-cancer pharmacy’s EHR feed. The two companion diagnostic structures differ in platform and tissue source: PDGFRA D842V uses DNA-based next-generation sequencing (FoundationOne CDx; FFPE solid tumor biopsy; GIST PDGFRA exon 18 missense; somatic in mesenchymal stromal cell of GI tract); KIT D816V uses allele-specific PCR (Ipsogen; ddPCR; or NGS exon 17 sequencing; bone marrow aspirate or peripheral blood; mast cell clonal expansion; somatic in hematopoietic mast cell progenitor). Both detect somatic mutations in the patient’s disease-driving cell population; both are entirely absent from the worker’s germline; both generate companion diagnostic reports that explicitly state “avapritinib is appropriate for this patient because [mutation] detected.”

The compounding AI inference risk: an EHS AI accessing a pharmacist’s dispensing context that includes both PDGFRA D842V FoundationOne CDx results (for GIST patients) and KIT D816V AS-PCR results (for ISM patients) simultaneously would encounter a data environment where avapritinib is consistently described as a molecule requiring activation-loop D→V mutation for therapeutic efficacy. The AI pattern recognition: avapritinib requires D816V/D842V (PDGFRA or KIT) → D→V mutations are somatic → workers are germline wild-type (Asp at both positions) → workers are pharmacologically ineligible as avapritinib targets → reduced occupational concern for wild-type workers. This four-step inference chain is structurally wrong at every step beyond the third: the pharmacological mechanism (step 1), the somatic mutation biology (step 2), and the worker wild-type status (step 3) are all correct; but step 4 — that pharmacological ineligibility reduces occupational carcinogenicity/genotoxicity hazard — is the category error. NIOSH HD Category 1 H340 H350 H361 reflects drug-substance genotoxicity (DNA damage potential at the molecular level: Ames test mutagenicity; in vitro chromosomal aberration; in vivo bone marrow micronucleus induction), reproductive toxicity (embryofetal development NOAEL in rats; rabbit developmental toxicity), and carcinogenicity potential — all assessed based on the molecule’s inherent chemical reactivity with DNA and cellular targets in normal cells. These genotoxicity assay systems use normal (non-D816V; non-D842V) cells; the genotoxic potential of avapritinib was observed in normal-KIT normal-PDGFRA cells. The H340 H350 H361 classification applies equally to a worker with KIT D816V-normal and to a hypothetical worker with KIT D816V or PDGFRA D842V (if such a worker existed) — the genotoxic hazard is the drug-molecule’s chemical interaction with DNA, not its pharmacological target engagement at Asp816/Asp842. Glyphward threshold 22 scoring encodes this correction: the dual companion diagnostic paradox contributes to the 4-point “other gap” component alongside the KIT D816V mutant-selective mechanism OEL absence (10 pts) and the Blueprint Medicines dual-NDA class-first gap (5 pts).

Integrating Glyphward into Avapritinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every avapritinib CAS 1703793-34-3 monitoring data ingestion point — before Cority at Blueprint Medicines Cambridge MA, before VelocityEHS at Patheon Cincinnati OH, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent + KIT D816V activation-loop mutant-selective mechanism (Asp816→Val removes Lys818 salt bridge → constitutive active open conformation; type I DFG-in active-conformation-selective 185-fold D816V/WT selectivity; PDGFRA D842V parallel exon 18 mechanism; KIT D816V-driven mast cell constitutive activation; mediator cascade histamine/PGD2/LTC4/tryptase in ISM; PIONEER serum tryptase pharmacodynamics; NAVIGATOR PDGFRA D842V ORR 91%; dual-disease dual-NDA complexity) absent from all OEL derivation frameworks [10 pts]; FIRST KIT D816V activation-loop mutant-selective inhibitor (NINETEENTH mechanism class) + FIRST systemic mastocytosis targeted therapy ever (NDA 214402 June 2021) + FIRST Blueprint Medicines dual-NDA holder null (NDA 212608 + NDA 214402) + dual companion diagnostic paradox (PDGFRA D842V FoundationOne CDx + KIT D816V allele-specific PCR) [5 pts]; Blueprint Cambridge MA + Patheon Cincinnati OH + Dana-Farber Boston MA [3 pts]; KIT D816V in patient mast cells/GIST tumor not in worker; activation-loop mutant-selective type I mechanism (requires D816V active conformation) mechanistically opposite to switch-control allosteric type V (locks inactive); both absent from all OEL derivation documents; dual-disease dual-NDA OEL scope absent; dual companion diagnostic combined EHR adjacency inference path absent; pyrrolotriazine scaffold OEL precedent absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_avapritinib(cas: str, reading_ugm3: float) -> dict:
    """Scan avapritinib with nineteenth-mechanism-class KIT-D816V-mutant-selective context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1703793-34-3"
                "reading_ugm3": reading_ugm3,
                "context": "nineteenth_mechanism_class_first_kit_d816v_activation_loop_mutant_selective_first_systemic_mastocytosis_pdgfra_d842v_gist_first_blueprint_medicines_dual_nda_null_dual_companion_diagnostic_paradox"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, kit_d816v_activation_loop_mutant_selective_flag,
    #                    pdgfra_d842v_flag, nineteenth_mechanism_class,
    #                    first_systemic_mastocytosis_targeted_therapy,
    #                    blueprint_medicines_dual_nda_null,
    #                    dual_companion_diagnostic_paradox, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_avapritinib("1703793-34-3", 0.00039))
    print(r)
    # {'hd_category': 1, 'kit_d816v_activation_loop_mutant_selective_flag': True,
    #  'pdgfra_d842v_flag': True, 'nineteenth_mechanism_class': True,
    #  'first_systemic_mastocytosis_targeted_therapy': True,
    #  'blueprint_medicines_dual_nda_null': True,
    #  'dual_companion_diagnostic_paradox': True, 'h340_h350_h361_absent': True}